Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw unusually-high trading volume on Thursday. 351,116 shares were traded during trading, an increase of 140% from the average daily volume of 146,077 shares. The stock last traded at $16.54 and had previously closed at $16.48.
Wall Street Analysts Forecast Growth
Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Astellas Pharma presently has an average rating of “Moderate Buy”.
Check Out Our Latest Analysis on Astellas Pharma
Astellas Pharma Price Performance
The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The firm has a market cap of $29.90 billion, a PE ratio of 12.11 and a beta of 0.06. The firm’s fifty day simple moving average is $15.19 and its two-hundred day simple moving average is $14.80.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). The firm had revenue of $3.98 billion during the quarter, compared to analysts’ expectations of $3.79 billion. Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. As a group, research analysts expect that Astellas Pharma Inc. will post 1.40 EPS for the current year.
Astellas Pharma Company Profile
Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.
Read More
- Five stocks we like better than Astellas Pharma
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
